MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis JOURNAL OF RHEUMATOLOGY Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., Schlichting, D. E., Beattie, S. D., Luchi, M., Macias, W. 2019; 46 (8): 887–95

View details for DOI 10.3899/jrheum.171469

View details for Web of Science ID 000478078100004